Showing 3121-3130 of 5956 results for "".
- State Strips Ex-USC Medical School Dean of License, Citing ‘An Appalling Lack of Judgment’https://modernod.com/news/state-strips-ex-usc-medical-school-dean-of-license-citing-an-appalling-lack-of-judgment/2479992/The California state agency that regulates physicians ordered USC’s former medical school dean stripped of his license to practice medicine, citing “an appalling lack of judgment” in his use of drugs an
- Apellis Pharmaceuticals’ APL-2 Receives FDA Fast Track Designation for the Treatment of Patients with GAhttps://modernod.com/news/apellis-pharmaceuticals-apl-2-receives-fast-track-designation-from-fda-for-the-treatment-of-patients-with-geographic-atrophy/2479993/Apellis Pharmaceuticals announced that the FDA has granted fast track designation to the company’s APL-2, a novel inhibitor of complement factor C3 as a next generation monotherapy, for the treatment of patients with geographic atrophy (GA). The FDA’s fast track program faci
- Heidelberg Engineering Announces Leadership Changeshttps://modernod.com/news/heidelberg-engineering-announces-leadership-changes/2480004/Heidelberg Engineering announced changes to the leadership team. Ali Tafreshi who has served in sales, marketing and research capacities in both the United States and German organizations
- Alzheimer’s Therapeutics Research Leader Dr. Roy Twyman Joins NeuroVision Imaging Boardhttps://modernod.com/news/alzheimers-therapeutics-research-leader-dr-roy-twyman-joins-neurovision-imaging-board/2480013/Roy Ervin Twyman, MD, PhD, an academic neurologist with nearly 20 years’ experience in neuroscience pharmaceutical drug development, will join the NeuroVision Imaging Board of Directors on July 20. NeuroVision is developing and studying an experimental, breakthrough, low-cost, noninvasive,
- Sue Anschutz-Rodgers Eye Center: A Highly Visible Legacy of Longstanding Philanthropic Partnershiphttps://modernod.com/news/sue-anschutz-rodgers-eye-center-a-highly-visible-legacy-of-longstanding-philanthropic-partnership/2480040/The University of Colorado Anschutz Medical Campus and UCHealth announced the naming of the UCHealth Eye Center program for philanthropist Sue Anschutz-Rodgers, who has made leadership gifts to accelerate innovative r
- Retinal Thinning Tied to Cognitive Declinehttps://modernod.com/news/retinal-thinning-tied-to-cognitive-decline/2480058/Thinning of the eye’s retinal nerve fiber layer (RNFL) appears to be a strong predictor of cognitive decline, new research shows, according to a report in Medscape. Investigators found healthy individuals with RNFL thinning w
- Oyster Point Pharma Gets Green Light From FDA to Proceed With Clinical Development of Dry Eye Treatmenthttps://modernod.com/news/oyster-point-pharma-gets-green-light-from-fda-to-proceed-with-clinical-development-of-dry-eye-treatment/2480060/Oyster Point Pharma announced that the FDA has cleared the company’s investigational new drug (IND) application to proceed with clinical development of OC-01, an investigational compound intended to stimulate natural tear film production in people with dry eye disease that is administered with a
- Bausch + Lomb Announces Licensing Agreement With Tangible Science for Use of Hydra-Peg Custom Contact Lens Coatinghttps://modernod.com/news/bausch-lomb-announces-licensing-agreement-with-tangible-science-for-use-of-hydra-peg-custom-contact-lens-coating/2480063/Bausch + Lomb announced that it has entered into a worldwide licensing agreement with Tangible Science, allowing Bausch + Lomb to offer the Tangible Hydra-PEG advanced contact lens coating technology for use with several of its Boston gas permeable (GP) materials and scleral lenses. Terms
- Staar Surgical Announces Resolution of FDA Warning Letterhttps://modernod.com/news/staar-surgical-announces-resolution-of-fda-warning-letter/2480080/STAAR Surgical announced that it received a close-out letter from the FDA on June 19, 2018 lifting a Warning Letter dated May 21, 2014. “The lifting of the Warning Letter is the result of a comprehensive remediation program that not only addressed the issues raised by the FDA in the 2014 W
- Kala Pharmaceuticals Announces Update to KPI-121 0.25% Development Planhttps://modernod.com/news/kala-pharmaceuticals-announces-update-to-kpi-121-0-25-development-plan/2480081/Kala Pharmaceuticals provided an update on the development plan for KPI-121 0.25%, which if approved could be the first FDA-approved product for the short-term treatment of dry eye disease.